Lilly USA President Foresees Strong GLP-1 Persistence in Medicare Population
LLY sits 49% above its 52-week low of $623.78.
Summary
Eli Lilly's USA President expressed expectations for strong persistence of the company's GLP-1 drugs within the Medicare population. This positive outlook on continued patient usage in a significant market segment provides valuable color on the sustained demand for Lilly's blockbuster Mounjaro and Zepbound. Coming just before the company's strong Q1 2026 earnings report and raised guidance, this commentary reinforces the robust growth trajectory of their key pharmaceutical assets. Traders will monitor actual prescription trends and payer coverage developments for these critical drugs.
At the time of this announcement, LLY was trading at $929.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $877.9B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.